Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Treatment options for carcinoma in situ testis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association between chemical pattern in breast milk and congenital cryptorchidism: modelling of complex human exposures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between congenital cryptorchidism in newborn boys and levels of dioxins and PCBs in placenta

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cumulative risk assessment of phthalate exposure of Danish children and adolescents using the hazard index approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Early breast development in girls after prenatal exposure to non-persistent pesticides

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer
Carcinoma in situ testis (CIS) is known as the precursor of germ cell cancer of the testis. International guidelines on diagnosis and treatment are inconsistent. Some countries offer routine biopsies of the contralateral testicle in relation to orchidectomy for testicular cancer, whereas other countries only offer this to high-risk patients. The treatment options range from orchidectomy and chemotherapy to radiotherapy and in rare cases surveillance. Results of the different treatment strategies are presented in this review. The optimal radiation dose is still not clarified. Most patients have been treated in the dose range of 16-20 Gy. Higher doses involve a higher risk of androgen insufficiency. Radiotherapy is recommended in patients with contralateral CIS. Orchidectomy should be offered in extragonadal germ cell cancer and CIS in one testicle, whereas patients with bilateral CIS should be offered radiation therapy. Patients who have undergone chemotherapy for testicular cancer are still at risk of developing CIS and we also recommend radiotherapy to the affected testicle in these patients. Cryopreservation should be offered before treatment is initiated and all patients should have their androgen status measured on a regular basis to find those cases where hormone substitution is needed.
OriginalsprogEngelsk
TidsskriftInternational Journal of Andrology
Vol/bind34
Udgave nummer4 Pt 2
Sider (fra-til)e32-6
ISSN0105-6263
DOI
StatusUdgivet - aug. 2011

ID: 33270271